Publications by authors named "Hamza Mahmood Bajwa"
Background: This study investigates clinical and biomarker differences between standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab therapy in multiple sclerosis (MS).
Methods: This is a prospective, double-arm, open-label, multi-center study in Denmark. Participants diagnosed with MS on ocrelizumab therapy >12 months were included ( = 184).
Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
J Neurol Neurosurg Psychiatry
November 2023
Article Synopsis
- The study examined breakthrough SARS-CoV-2 infections in multiple sclerosis patients treated with ocrelizumab before getting BNT162b2 mRNA vaccinations.
- A total of 54 MS patients were followed, with 32 (59.3%) testing positive for the virus; however, all cases were mild and manageable.
- Results showed that non-infected participants had significantly higher antibody levels after the third vaccination, indicating a potential need for ongoing vaccine development for better protection in this patient group.
Objective: To examine humoral and cellular response in multiple sclerosis patients on anti-CD20 therapy after third BNT162b2 mRNA SARS-CoV-2 vaccination.
Methods: A prospective longitudinal study design from first throughout third vaccination in Danish and American MS centers. All participants were treated with ocrelizumab.